Paroxysmal Atrial Fibrillation
Conditions
Brief summary
This is a prospective, descriptive study. Safety endpoints will not be assessed. All eligible patients that have a history of paroxysmal atrial fibrillation and an indication to undergo Micra AV2 device placement as per standard of care (SOC) across the participating sites within the Northwell Health System can be included in this analysis. Micra AV2 placement indications will be at the discretion of the treating electrophysiologist, but are expected to be predominantly atrioventricular block. Periodic device interrogations will be reviewed for the presence of effective atrial tracking during sinus rhythm . The presence of paroxysmal atrial fibrillation and the degree to which atrial activity and A4 amplitude trend changes will be assessed using a designated Medtronic Research Holter monitor that detects Micra AV2 signals at any point in the study during a episodes of sinus rhythm and atrial fibrillation. Patients who have atrial fibrillation during index hospitalization will undergo placement of the Medtronic Holter monitor as part of the standard of care index hospitalization. Eligible outpatients will undergo placement of the Medtronic Research Holter Monitor in the office.
Interventions
DEVICEMicra AV2- Observational
All eligible patients that have a history of paroxysmal atrial fibrillation and an indication to undergo Micra AV2 device placement as per standard of care (SOC) across the participating sites within the Northwell Health System can be included in this analysis. Micra AV2 placement indications will be at the discretion of the treating electrophysiologist, but are expected to be predominantly atrioventricular block.
Sponsors
Northwell Health
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Participant or legally authorized representative (LAR) provides authorization and/or consent per institution and geographical requirements * Participant has been implanted with the Micra AV2 device or is intended to receive or be treated with an eligible Micra AV2 device as per standard of care. * Participants with a history of paroxysmal atrial fibrillation undergoing Micra AV2 implantation, as per standard of care. * Age 18-85 years old with the ability to consent for the procedure * Participant is consented within the enrollment window of the therapy received, as applicable * English Speaking
Exclusion criteria
* Participant who is, or is expected to be, inaccessible for follow-up * Participation is excluded by local law * Participant is currently enrolled or plans to enroll in concurrent drug/device study that may confound the study results * Participant with persistent/chronic atrial fibrillation * Prisoner or cognitively impaired due to the study procedures involving independent wearing of the holter monitor for research purposes.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the prevalence of atrial fibrillation in the Micra AV2 patients | Through study completion, an average of 6 months | — |
| To evaluate A4 amplitude trend changes during sinus rhythm and atrial fibrillation | Through study completion, an average of 6 months | To evaluate the presence of paroxysmal atrial fibrillation and the degree to which atrial activity and A4 amplitude trend changes will be assessed using a designated Medtronic Research Holter monitor that detects Micra AV2 signals at any point in the study during episodes of sinus rhythm and atrial fibrillation. |
| To determine the ability of the Micra AV2 device to detect the presence and burden of atrial fibrillation | Through study completion, an average of 6 months | Micra AV2 placement indications will be at the discretion of the treating electrophysiologist, but are expected to be predominantly atrioventricular block. Periodic device interrogations will be reviewed for the presence of effective atrial tracking during sinus rhythm. |
Countries
United States
Contacts
CONTACTSalome Elia Reddy, PhD
CONTACTEmma Grace Lao
PRINCIPAL_INVESTIGATORHaisam Ismail, MD
Northwell Health
Outcome results
None listed